These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1450076)

  • 1. Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice.
    Kapp U; Wolf J; von Kalle C; Tawadros S; Röttgen A; Engert A; Fonatsch C; Stein H; Diehl V
    Ann Oncol; 1992 Sep; 3 Suppl 4():21-3. PubMed ID: 1450076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice.
    Kapp U; Düx A; Schell-Frederick E; Banik N; Hummel M; Mücke S; Fonatsch C; Bullerdiek J; Gottstein C; Engert A
    Ann Oncol; 1994; 5 Suppl 1():121-6. PubMed ID: 7513537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth of Hodgkin cell lines in severely combined immunodeficient mice.
    von Kalle C; Wolf J; Becker A; Sckaer A; Munck M; Engert A; Kapp U; Fonatsch C; Komitowski D; Feaux de Lacroix W
    Int J Cancer; 1992 Dec; 52(6):887-91. PubMed ID: 1459730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hodgkin's lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice.
    Kapp U; Wolf J; Hummel M; Pawlita M; von Kalle C; Dallenbach F; Schwonzen M; Krueger GR; Müller-Lantzsch N; Fonatsch C
    Blood; 1993 Aug; 82(4):1247-56. PubMed ID: 8353287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
    Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
    Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice.
    Bargou RC; Mapara MY; Zugck C; Daniel PT; Pawlita M; Döhner H; Dörken B
    J Exp Med; 1993 May; 177(5):1257-68. PubMed ID: 8386741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
    Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
    Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homing and antigenic characterization of a human non-Hodgkin's lymphoma B cell line in severe combined immunodeficient (SCID) mice.
    de Kroon JF; Kluin PM; Kluin-Nelemans HC; Willemze R; Falkenburg JH
    Leukemia; 1994 Aug; 8(8):1385-91. PubMed ID: 8057678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observations on cell lines derived from a patient with Hodgkin's disease.
    Friend C; Marovitz W; Henie G; Henie W; Tsuei D; Hirschhorn K; Holland JG; Cuttner J
    Cancer Res; 1978 Aug; 38(8):2581-91. PubMed ID: 78764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth of cultured cells from patients with Hodgkin's disease and transplantation into nude mice.
    Zamecnik PC; Long JC
    Proc Natl Acad Sci U S A; 1977 Feb; 74(2):754-8. PubMed ID: 265539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
    de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
    Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
    Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
    Engert A; Gottstein C; Winkler U; Amlot P; Pileri S; Diehl V; Thorpe P
    Leuk Lymphoma; 1994 May; 13(5-6):441-8. PubMed ID: 8069189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
    Barth S; Huhn M; Matthey B; Schnell R; Tawadros S; Schinköthe T; Lorenzen J; Diehl V; Engert A
    Int J Cancer; 2000 Jun; 86(5):718-24. PubMed ID: 10797296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins.
    Winkler U; Gottstein C; Schön G; Kapp U; Wolf J; Hansmann ML; Bohlen H; Thorpe P; Diehl V; Engert A
    Blood; 1994 Jan; 83(2):466-75. PubMed ID: 8286745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
    Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
    Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the colonization of unirradiated and irradiated SCID mice by human lymphoma and non-malignant lymphoid cells.
    Zubair AC; Ali SA; Rees RC; Goepel JR; Winfield DA; Goyns MH
    Leuk Lymphoma; 1996 Aug; 22(5-6):463-71. PubMed ID: 8882960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a novel malignant B cell line with t(14;18) and t(4;11) established from a patient with acute monoblastic leukemia.
    de Kroon JF; Kluin-Nelemans HC; Kluin PM; Schuuring E; van Bergen CA; Oving I; Wessels H; Willemze R; Falkenburg JH
    Exp Hematol; 1997 Sep; 25(10):1062-8. PubMed ID: 9293903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth of primary T-cell non-Hodgkin's lymphomata in SCID-hu mice: requirement for a human lymphoid microenvironment.
    Waller EK; Kamel OW; Cleary ML; Majumdar AS; Schick MR; Lieberman M; Weissman IL
    Blood; 1991 Nov; 78(10):2650-65. PubMed ID: 1824259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.